In the phase III RASolute-302 trial, the pan-RAS inhibitor daraxonrasib reportedly doubled median overall survival compared with chemotherapy in second-line metastatic pancreatic ductal adenocarcinoma. The study’s headline outcome reframes pan-RAS targeting as a potential survival-moving approach in an area where second-line options often deliver limited benefit. The result also adds to the competitive landscape of downstream RAS pathway inhibitors and combinations, where prior efforts have frequently fallen short of durable survival improvements. For developers and investors, the most actionable takeaway is that RAS-path inhibition—if paired with the right regimen and patient selection—can translate into meaningful clinical endpoints in late-stage disease.